Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and Wegovy - Barrons - Barron's
barrons.comSubmitted by barrons9707 in business
Novo Nordisk now expects sales growth in 2023 of between 32% and 38%.
Submitted by barrons9707 in business
Novo Nordisk now expects sales growth in 2023 of between 32% and 38%.